High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:18
|
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Which Has a Superior Dosimetric Profile in Image-guided High-dose-rate Brachytherapy of Cervix - Tandem Ovoid or Tandem Ring Applicator?
    Rangarajan, Ramya
    JOURNAL OF MEDICAL PHYSICS, 2025, 50 (01) : 55 - 59
  • [2] Dosimetric impact of applicator displacement on three-dimensional image-guided high-dose-rate brachytherapy treatments for cervical cancer
    Jayarathna, Sandun
    Hoang, Matthew
    Badkul, Rajeev
    Hoover, Andrew
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2023, 15 (05) : 334 - 343
  • [3] Clinical outcomes of abbreviated high dose-rate brachytherapy in locally advanced cervical cancer: lessons from the COVID pandemic for high dose-rate fractionation
    Chopra, Supriya
    Samanta, Asesh
    Nagar, Arunima
    Mittal, Prachi
    Gupta, Ankita
    Mulani, Jaahid
    Jain, Jeevanshu
    Kohle, Satish
    Ghadi, Yogesh
    Rath, Sushmita
    Gulia, Seema
    Ghosh, Jaya
    Gupta, Sudeep
    BRACHYTHERAPY, 2025, 24 (01) : 1 - 10
  • [4] Dosimetric and toxicity comparison between Syed-Neblett and Fletcher-Suit-Delclos Tandem and Ovoid applicators in high dose rate cervix cancer brachytherapy
    Portocarrero-Bonifaz, Andres
    Syed, Salman
    Kassel, Maxwell
    Mckenzie, Grant W.
    Shah, Vishwa M.
    Forry, Bryce M.
    Gaskins, Jeremy T.
    Sowards, Keith T.
    Avula, Thulasi Babitha
    Masters, Adrianna
    Silva, Scott R.
    BRACHYTHERAPY, 2024, 23 (04) : 397 - 406
  • [5] Dosimetric and radiobiological evaluation of treatment plan for cervical cancer high-dose-rate intracavitary brachytherapy
    Kaur, Gurpreet
    Garg, Pardeep
    Srivastava, Anoop Kumar
    Gaur, Garima
    Sheetal
    Grover, Romikant
    Kang, Manraj Singh
    Dangwal, Vinod Kumar
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (03) : 253 - 259
  • [6] High-dose-rate brachytherapy using inverse planning optimization with tandem and ovoid applicators for locally advanced cervical cancer: a simulation study
    Yaegashi, Yuji
    Sasaki, Kohei
    RADIOLOGICAL PHYSICS AND TECHNOLOGY, 2021, 14 (03) : 262 - 270
  • [7] A novel two-step optimization method for tandem and ovoid high-dose-rate brachytherapy treatment for locally advanced cervical cancer
    Sharma, Manju
    Fields, Emma C.
    Todor, Dorin A.
    BRACHYTHERAPY, 2015, 14 (05) : 613 - 618
  • [8] Small bowel dose in subserosal tandem insertion during cervical cancer brachytherapy
    Tsai, Yu-Lun
    Yu, Pei-Chieh
    Lui, Louis Tak
    Shaw, Suzun
    Wu, Ching-Jung
    MEDICAL DOSIMETRY, 2020, 45 (03) : E1 - E9
  • [9] Uterine perforation and its dosimetric implications in cervical cancer high-dose-rate brachytherapy
    Bahadur, Yasir A.
    Eltaher, Moho M.
    Hassouna, Ashraf H.
    Attar, Mohammad A.
    Constantinescu, Camelia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (01) : 41 - 47
  • [10] A comparison of tandem ring and tandem ovoid treatment as a curative brachytherapy component for cervical cancer
    Gursel, Sukriye Bilge
    Serarslan, Alparslan
    Meydan, Ahmet Deniz
    Okumus, Nilgun
    Yasayacak, Tenzile
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (02) : 111 - 117